EP3525798A4 - Verfahren zur verringerung der proteinurie bei einem menschlichen probanden, der an immunglobulin-a-nephropathie leidet - Google Patents

Verfahren zur verringerung der proteinurie bei einem menschlichen probanden, der an immunglobulin-a-nephropathie leidet Download PDF

Info

Publication number
EP3525798A4
EP3525798A4 EP17861108.3A EP17861108A EP3525798A4 EP 3525798 A4 EP3525798 A4 EP 3525798A4 EP 17861108 A EP17861108 A EP 17861108A EP 3525798 A4 EP3525798 A4 EP 3525798A4
Authority
EP
European Patent Office
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17861108.3A
Other languages
English (en)
French (fr)
Other versions
EP3525798A1 (de
Inventor
Nigel John BRUNSKILL
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Publication of EP3525798A1 publication Critical patent/EP3525798A1/de
Publication of EP3525798A4 publication Critical patent/EP3525798A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
EP17861108.3A 2016-10-13 2017-10-12 Verfahren zur verringerung der proteinurie bei einem menschlichen probanden, der an immunglobulin-a-nephropathie leidet Pending EP3525798A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (2)

Publication Number Publication Date
EP3525798A1 EP3525798A1 (de) 2019-08-21
EP3525798A4 true EP3525798A4 (de) 2020-07-08

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17861108.3A Pending EP3525798A4 (de) 2016-10-13 2017-10-12 Verfahren zur verringerung der proteinurie bei einem menschlichen probanden, der an immunglobulin-a-nephropathie leidet

Country Status (18)

Country Link
EP (1) EP3525798A4 (de)
JP (1) JP6893554B2 (de)
KR (1) KR102348939B1 (de)
CN (2) CN110177557A (de)
AU (1) AU2017342428B2 (de)
BR (1) BR112019007426A2 (de)
CA (2) CA3039927C (de)
CL (2) CL2019000909A1 (de)
GE (1) GEP20247587B (de)
IL (1) IL265981A (de)
JO (1) JOP20190068A1 (de)
MA (1) MA46541A (de)
MX (1) MX2019004074A (de)
PH (1) PH12019500711A1 (de)
SG (1) SG11201902941UA (de)
UA (1) UA126908C2 (de)
WO (1) WO2018071701A1 (de)
ZA (1) ZA201902933B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151481A1 (en) * 2011-05-04 2012-11-08 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
US20130266560A1 (en) * 2011-04-08 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2015058143A1 (en) * 2013-10-17 2015-04-23 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20180153988A1 (en) * 2016-08-31 2018-06-07 Omeros Corporation Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374819B1 (de) * 2003-05-12 2017-03-22 Helion Biotech ApS Antikörper gegen MASP-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
ES2617920T3 (es) * 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130266560A1 (en) * 2011-04-08 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2012151481A1 (en) * 2011-05-04 2012-11-08 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
WO2015058143A1 (en) * 2013-10-17 2015-04-23 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US20180153988A1 (en) * 2016-08-31 2018-06-07 Omeros Corporation Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
BR112019007426A2 (pt) 2019-07-02
CN116726163A (zh) 2023-09-12
NZ753260A (en) 2021-11-26
CN110177557A (zh) 2019-08-27
CA3039927A1 (en) 2018-04-19
AU2017342428B2 (en) 2021-02-04
AU2017342428A1 (en) 2019-05-23
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
JP2019534271A (ja) 2019-11-28
EP3525798A1 (de) 2019-08-21
ZA201902933B (en) 2023-05-31
MX2019004074A (es) 2019-06-10
PH12019500711A1 (en) 2019-11-18
KR102348939B1 (ko) 2022-01-12
JP6893554B2 (ja) 2021-06-23
IL265981A (en) 2019-06-30
MA46541A (fr) 2019-08-21
WO2018071701A1 (en) 2018-04-19
JOP20190068A1 (ar) 2019-04-01
CA3039927C (en) 2023-10-10
UA126908C2 (uk) 2023-02-22
CA3210384A1 (en) 2018-04-19
SG11201902941UA (en) 2019-05-30
KR20190063475A (ko) 2019-06-07
GEP20247587B (en) 2024-01-25

Similar Documents

Publication Publication Date Title
EP3557339A4 (de) Verknüpftes steuerungsverfahren für ein internet-der-dinge-gateway sowie internet-der-dinge-gateway
EP3430619A4 (de) Modulare systeme und verfahren zur selektiven aktivierung cloud-basierter unterstützender technologien
EP3369002A4 (de) Verfahren und vorrichtung zur erleichterung der vorhersage von kundenabsichten
EP3183727A4 (de) System und verfahren zur sprachvalidierung
EP3140763A4 (de) Bindungsaffinitätsvorhersagesystem und -verfahren
EP3238313A4 (de) Verfahren zur adaptiven bedarfsladungsreduzierung
EP3164260A4 (de) Systeme und verfahren zur herstellung von gelenkelementen
EP3209803A4 (de) Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika
EP3203964A4 (de) System und verfahren zur einstellung eines rollstuhlsitzes
EP3312839A4 (de) Vorrichtung zur unterstützung bidirektionaler gespräche und verfahren zur unterstützung bidirektionaler gespräche
EP3186025A4 (de) Verfahren und system zum schweissen
EP3131498A4 (de) Exoskelettsystem zum lasttransport
EP3539130A4 (de) Vorrichtungen und verfahren zur speicherausrichtung
EP3162107A4 (de) System und verfahren zur koordinierten strahlformung in einem überlappenden basisdienstset in einem wlan
EP3417179B8 (de) Verbindungsmittel und verfahren zum verbinden zweier bauteile
EP3143511A4 (de) System und verfahren für affinitätsbasierte netzwerkkonfiguration
EP3162142A4 (de) System und verfahren zur koordinierten strahlformung in einem überlappenden basisdienstset in einem wlan
EP3103578A4 (de) Schweissstruktur und verfahren zur herstellung einer schweissstruktur
EP3280437A4 (de) Egfr-gerichtete car-therapie für glioblastom
EP3308223A4 (de) Mikronetzsystem und steuergerät
EP3179117A4 (de) Bewegliche vorrichtung, beweglicher sitz und verfahren zur herstellung einer beweglichen vorrichtung
EP3118210A4 (de) Verfahren zur aufreinigung von immunglobulin
EP3142176A4 (de) Brennstoffzellensystem und verfahren zur steuerung des brennstoffzellensystems
EP3161762A4 (de) Verfahren und system zur ermöglichung einer zahlung
EP3167214A4 (de) Gekrümmter shunt zur magnetkurvenkrümmung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190503

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031710500

Ipc: A61K0039395000

A4 Supplementary search report drawn up and despatched

Effective date: 20200605

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20200529BHEP

Ipc: A61K 39/395 20060101AFI20200529BHEP

Ipc: A61K 45/06 20060101ALI20200529BHEP

Ipc: A61P 13/12 20060101ALI20200529BHEP

Ipc: C07K 16/40 20060101ALI20200529BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230508

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240112